KORU Medical Systems, Inc. (KRMD) P/E Ratio History
Deep ValueTrading at -68.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2007–2020
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, KORU Medical Systems, Inc. (KRMD) trades at a price-to-earnings ratio of -68.3x, with a stock price of $3.90 and trailing twelve-month earnings per share of $-0.05.
The current P/E is 111% below its 5-year average of 607.2x. Over the past five years, KRMD's P/E has ranged from a low of 14.4x to a high of 6907.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, KRMD trades at a 409% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, KRMD trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KRMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KRMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KRMD P/E vs Peers
Drug delivery and infusion consumables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $190M | 30.4 | - | +182%Best | |
| $2B | 37.3 | 1.93 | +31% | |
| $52B | 24.7Lowest | 1.49Best | -1% | |
| $4B | 31.6 | - | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KRMD Historical P/E Data (2007–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q2 | - | $8.98 | $0.00 | 6907.7x | +2622% |
| FY2020 Q1 | - | $7.50 | $0.03 | 250.0x | -1% |
| FY2019 Q4 | - | $6.53 | $0.02 | 366.9x | +45% |
| FY2019 Q3 | Sep 30 2019 | $3.95 | $0.01 | 369.2x | +45% |
| FY2019 Q2 | Jun 30 2019 | $2.88 | $0.00 | 3600.0x | +1319% |
| FY2019 Q1 | Mar 31 2019 | $1.60 | $0.01 | 141.6x | -44% |
| FY2018 Q4 | Dec 31 2018 | $1.65 | $0.02 | 68.5x | -73% |
| FY2018 Q3 | Sep 30 2018 | $1.65 | $0.05 | 34.9x | -86% |
| FY2018 Q2 | Jun 30 2018 | $1.38 | $0.05 | 29.2x | -88% |
| FY2018 Q1 | Mar 31 2018 | $1.30 | $0.04 | 33.7x | -87% |
| FY2017 Q4 | Dec 31 2017 | $1.25 | $0.03 | 50.0x | -80% |
| FY2017 Q3 | Sep 30 2017 | $0.53 | $0.01 | 65.4x | -74% |
| FY2016 Q3 | Aug 31 2016 | $0.44 | $0.01 | 84.6x | -67% |
| FY2016 Q2 | - | $0.35 | $0.02 | 20.2x | -92% |
| FY2016 Q1 | Feb 29 2016 | $0.57 | $0.02 | 26.1x | -90% |
| FY2015 Q4 | Nov 30 2015 | $0.41 | $0.02 | 19.9x | -92% |
| FY2015 Q3 | Aug 31 2015 | $0.38 | $0.02 | 20.5x | -92% |
| FY2015 Q2 | May 31 2015 | $0.45 | $0.02 | 24.2x | -90% |
| FY2015 Q1 | Feb 28 2015 | $0.40 | $0.02 | 16.3x | -94% |
| FY2014 Q4 | Nov 30 2014 | $0.39 | $0.03 | 14.4x | -94% |
| FY2014 Q3 | Aug 31 2014 | $0.34 | $0.03 | 11.7x | -95% |
| FY2014 Q2 | May 31 2014 | $0.24 | $0.02 | 11.4x | -96% |
| FY2014 Q1 | Feb 28 2014 | $0.21 | $0.02 | 11.1x | -96% |
| FY2013 Q4 | Nov 30 2013 | $0.20 | $0.02 | 13.5x | -95% |
| FY2013 Q3 | Aug 31 2013 | $0.21 | $0.01 | 17.5x | -93% |
| FY2013 Q2 | May 31 2013 | $0.21 | $0.02 | 10.4x | -96% |
| FY2013 Q1 | - | $0.21 | $0.02 | 10.3x | -96% |
| FY2012 Q4 | Nov 30 2012 | $0.26 | $0.02 | 11.3x | -96% |
| FY2012 Q3 | Aug 31 2012 | $0.21 | $0.03 | 8.0x | -97% |
| FY2012 Q2 | - | $0.22 | $0.02 | 11.2x | -96% |
| FY2012 Q1 | Feb 29 2012 | $0.25 | $0.03 | 9.3x | -96% |
| FY2011 Q4 | Nov 30 2011 | $0.26 | $0.03 | 9.7x | -96% |
| FY2011 Q3 | Aug 31 2011 | $0.36 | $0.03 | 13.3x | -95% |
| FY2011 Q2 | - | $0.35 | $0.03 | 13.0x | -95% |
| FY2011 Q1 | Feb 28 2011 | $0.18 | $0.02 | 9.4x | -96% |
| FY2010 Q4 | - | $0.13 | $0.03 | 4.5x | -98% |
| FY2010 Q3 | - | $0.14 | $0.03 | 5.5x | -98% |
| FY2010 Q2 | May 31 2010 | $0.14 | $0.03 | 5.6x | -98% |
| FY2010 Q1 | Feb 28 2010 | $0.19 | $0.03 | 7.6x | -97% |
| FY2009 Q4 | Nov 30 2009 | $0.19 | $0.02 | 9.2x | -96% |
| FY2009 Q3 | Aug 31 2009 | $0.17 | $0.03 | 5.8x | -98% |
| FY2009 Q2 | May 31 2009 | $0.17 | $0.04 | 4.8x | -98% |
| FY2009 Q1 | Feb 28 2009 | $0.17 | $0.04 | 3.8x | -99% |
| FY2008 Q4 | Nov 30 2008 | $0.27 | $0.03 | 8.4x | -97% |
| FY2008 Q3 | Aug 31 2008 | $0.18 | $0.03 | 5.6x | -98% |
| FY2008 Q2 | May 31 2008 | $0.21 | $0.03 | 6.4x | -97% |
| FY2008 Q1 | Feb 29 2008 | $0.10 | $0.02 | 6.1x | -98% |
| FY2007 Q4 | Nov 30 2007 | $0.16 | $0.02 | 10.3x | -96% |
| FY2007 Q3 | Aug 31 2007 | $0.12 | $0.00 | 36.4x | -86% |
Average P/E for displayed period: 253.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KRMD — Frequently Asked Questions
Quick answers to the most common questions about buying KRMD stock.
What is KRMD's P/E ratio?
KORU Medical Systems, Inc. (KRMD) trailing twelve-month P/E ratio is -68.3x, based on TTM diluted EPS of $-0.05. The 5-year average P/E is 607.2x and the historical range spans 14.4x to 6907.7x.
Is KRMD stock overvalued or undervalued?
KRMD trades at -68.3x P/E, below its 5-year average of 607.2x. At the 0th percentile of its historical range (14.4x–6907.7x), the stock is priced at a discount to its own history.
Is KRMD stock expensive?
No, KRMD is not expensive on a historical basis. The current P/E of -68.3x is below the 5-year average of 607.2x and sits at the 0th percentile of its valuation range.
What is KRMD's historical P/E range?
Over the past 5 years, KRMD's P/E ratio has ranged from 14.4x to 6907.7x, with a median of 50.0x and an average of 607.2x. The current P/E of -68.3x places the stock at the 0th percentile of this range. Full historical data spans 2007–2020.
How does KRMD's P/E compare to the S&P 500?
KRMD trades at -68.3x P/E versus the S&P 500 median of 24.4x. The 380% discount to the market suggests lower growth expectations or perceived higher risk.
How does KRMD's valuation compare to Healthcare peers?
KORU Medical Systems, Inc. P/E of -68.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KRMD's PEG ratio?
KRMD PEG ratio is N/A, based on a P/E of -68.3x and EPS growth of 56.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KRMD's earnings yield?
KRMD earnings yield is N/A, the inverse of its -68.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.